Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Chronic Spontaneous Urticaria
NCT04893980Phase 3Unknown
- Sponsor
- The Second Xiangya Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of aldesleukin in chronic spontaneous urticaria (CSU), sponsored by The Second Xiangya Hospital. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04893980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893980.